Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

2024

Vitamin D Binding Protein Isoforms and Cancer Risk

Sample size: 154987 publication 10 minutes Evidence: moderate

Author Information

Author(s): Weinstein Stephanie J., Parisi Dominick, Mondul Alison M., Layne Tracy M., Huang Jiaqi, Stolzenberg-Solomon Rachael Z., Ziegler Regina G., Purdue Mark P., Huang Wen-Yi, Abnet Christian C., Freedman Neal D., Yu Kai, Albanes Demetrius

Primary Institution: Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, United States of America

Hypothesis

Do vitamin D binding protein genetic isoforms modify the association between serum vitamin D levels and cancer risk?

Conclusion

Vitamin D binding protein isoforms do not significantly modify the association between vitamin D levels and cancer risk, except for bladder cancer.

Supporting Evidence

Vitamin D binding protein isoforms were analyzed in relation to cancer risk in a large cohort.
Bladder cancer risk was significantly modified by vitamin D binding protein isoforms.
Overall cancer risk did not show significant associations with vitamin D binding protein isoforms.

Takeaway

This study looked at how different forms of a protein that carries vitamin D in the body might change the risk of getting cancer. They found that while most cancers weren't affected, bladder cancer risk was influenced by these protein forms.

Methodology

The study used logistic regression models to analyze data from the PLCO Trial, comparing cancer cases and controls based on vitamin D levels and genetic data.